Switzerland· 68221001
MenQuadfi, solution injectable
A meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert product containing polysaccharida neisseriae meningitidis a, polysaccharida neisseriae meningitidis c, polysaccharida neisseriae meningitidis y, toxoidum tetani, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH08 (meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AH08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- polysaccharida neisseriae meningitidis A, polysaccharida neisseriae meningitidis C, polysaccharida neisseriae meningitidis Y, toxoidum tetani
- Manufacturer
- Sanofi-Aventis (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- J07AH08
- ATC class
- Meningokokken A, C, Y, W-135, tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680682210015Durchstf 0.5 mlCHF 61.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH08
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert, as other registers publish it.
- CanadaMENACTRASANOFI PASTEUR LIMITED
- PolandMenQuadfiSanofi Winthrop Industrie
- FinlandMenQuadfiSanofi Winthrop Industrie
- BelgiumMenQuadfiSanofi Winthrop Industrie
- IcelandMenQuadfiSanofi Winthrop Industrie
- DenmarkMenQuadfiSanofi Winthrop Industrie
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/037bdad9-6f5f-4d51-96b8-7da07bebf188 GET /v1/drugs/037bdad9-6f5f-4d51-96b8-7da07bebf188?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "polysaccharida neisseriae meningitidis a 10 mcg + polysaccharida neisseriae meningitidis c 10 mcg + polysaccharida neisseriae meningitidis w135 10 mcg + polysaccharida neisseriae meningitidis y 10 mcg + vaccinum meningitidis polysaccharid. tetravalens a, c, w135, y conjugatum t",
"valid_from": "2023-06-01",
"limitations": "[{\"description\":\"Kostenübernahme bei Kindern ab 1 Jahr.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-01-01\"}]",
"galenic_form": "Inj Lös",
"therapeutic_area": null,
"sl_inclusion_date": "2023-06-01",
"self_retention_pct": 10
}See everything about meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.